š« What Is Sotatercept-csrk? Winrevairā¢ (sotatercept-csrk) is a pioneering biologic therapy developed by Merck, approved by the FDA in March 2024 for the treatment of adults with pulmonary arterial hypertension (PAH), classified as World Healthā¦
Antibiotic resistance poses a significant challenge to modern medicine, rendering many traditional antibiotics less effective against certain bacterial infections. In response, new treatments like Exblifep have been developed to address resistant pathogens. This article delvesā¦
Caffeic Acid tablets, as a drug with the functions of hemostasis and leukocyte elevation, have demonstrated remarkable efficacy in clinical application in several departments in recent years. Wide Clinical Application According to Tencent News, Caffeicā¦
Tryvio (aprocitentan) is a novel antihypertensive medication developed by Idorsia Pharmaceuticals. Approved by the U.S. Food and Drug Administration (FDA) in March 2024, it offers a new therapeutic option for patients with resistant hypertensionāthose whoseā¦
What Is Zelsuvmi Used For? ZELSUVMIā¢ (berdazimer) is a first-in-class topical medication that was approved by the U.S. Food and Drug Administration on January 5, 2024, making it the first new drug for the treatmentā¦
In March 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra (resmetirom), marking a significant milestone as the first approved treatment for nonalcoholic steatohepatitis (NASH), in adults with moderate to advancedā¦
Tevimbra, known generically as tislelizumab-jsgr, is a humanized IgG4 monoclonal antibody developed by BeiGene. It functions as a PD-1 inhibitor, aiming to enhance the body’s immune response against cancer cells. Approved for various indications, Tevimbraā¦
Phil GattonePresident and CEO, National Bleeding Disorders Foundationā…. Qfitlia takes a novel approach to providing protection for people living with hemophilia while reducing the frequency of dosing for patients and their families.ā Hemophilia is aā¦
Letybo(letibotulinumtoxinA-wlbg), developed by South Korean biopharmaceutical company Hugel, has recently received FDA approval for the treatment of moderate to severe glabellar lines (frown lines) in adults. Known as Botulax in South Korea, Letybo has beenā¦
Niktimvo (axatilimab-csfr) is a prescription medicine used to treat chronic graft-versus-host disease (cGVHD) if you have received at least 2 prior treatments and they have not worked. Niktimvo works by targeting the drivers of inflammation and fibrosis thatā¦
In a key step forward in the field of rare disease treatment, the U.S. Food and Drug Administration (FDA) has officially approved Miplyffa (generic name: Arimoclomol), developed by Zevra Therapeutics, is intended for the treatmentā¦
Lazcluze is a cancer medicine used to treat adults with advanced non-small cell lung cancer (NSCLC) who have not been treated before. It is used in people whose cancer cells have certain mutations (changes) inā¦
